PBRM1, one of the most frequently mutated genes in ccRCC, has been linked in several studies to improved outcomes with nivolumab and with antiangiogenic agents such as sunitinib, suggesting that PBRM1 status may help refine treatment selection despite some remaining controversy [18,19,20,21,22,23,24,25,26,27,28,29,30,31,44,61]. The gene discussed is PBRM1; the disease is nonpapillary renal cell carcinoma.